124 related articles for article (PubMed ID: 1909607)
41. Pharmacological characterization of serotonin receptors involved in the control of prolactin secretion.
Di Renzo G; Amoroso S; Taglialatela M; Canzoniero L; Basile V; Fatatis A; Annunziato L
Eur J Pharmacol; 1989 Mar; 162(2):371-3. PubMed ID: 2524399
[TBL] [Abstract][Full Text] [Related]
42. Effect of dopamine infusion on serum prolactin concentration in normal and hyperprolactinaemic subjects.
Reschini E; Ferrari C; Peracchi M; Fadini R; Meschia M; Crosignani PG
Clin Endocrinol (Oxf); 1980 Dec; 13(6):519-23. PubMed ID: 7226569
[TBL] [Abstract][Full Text] [Related]
43. Growth hormone releasing factor stimulates and somatostatin inhibits prolactin release from human mixed somatotroph-lactotroph adenomas in perifusion.
Serri O
Clin Endocrinol (Oxf); 1987 Dec; 27(6):675-82. PubMed ID: 2901301
[TBL] [Abstract][Full Text] [Related]
44. Dopaminergic receptors in human prolactin-secreting adenomas: a quantitative study.
Bression D; Brandi AM; Martres MP; Nousbaum A; Cesselin F; Racadot J; Peillon F
J Clin Endocrinol Metab; 1980 Nov; 51(5):1037-44. PubMed ID: 7419680
[TBL] [Abstract][Full Text] [Related]
45. The role of serum PRL bioactivity evaluation in hyperprolactinaemic women with different menstrual disorders.
Kostrzak A; Warenik-Szymankiewicz A; Meczekalski B
Gynecol Endocrinol; 2009 Dec; 25(12):799-806. PubMed ID: 19905999
[TBL] [Abstract][Full Text] [Related]
46. Monolayer and suspension culture of human prolactin-secreting pituitary adenoma.
Kletzky OA; Marrs RP; Rundall TT; Weiss MH; Beierle JW
Am J Obstet Gynecol; 1980 Nov; 138(6):660-4. PubMed ID: 7435530
[TBL] [Abstract][Full Text] [Related]
47. Mediation of ACTH and prolactin responses to 5-HTP by 5-HT2 receptors.
Gartside SE; Cowen PJ
Eur J Pharmacol; 1990 Apr; 179(1-2):103-9. PubMed ID: 2163847
[TBL] [Abstract][Full Text] [Related]
48. Immunohistochemical detection of glycoprotein hormone alpha subunit in somatoprolactinic and pure somatotroph adenomas.
Vantyghem MC; Cortet C; Bauters C; Gevaert MH; Dewailly D; Lefebvre J; Mazzucca M
J Endocrinol Invest; 1998; 21(7):434-40. PubMed ID: 9766257
[TBL] [Abstract][Full Text] [Related]
49. The value of prolactin in predicting prolactinοma in hyperprolactinaemic polycystic ovarian syndrome.
Kyritsi EM; Dimitriadis GK; Angelousi A; Mehta H; Shad A; Mytilinaiou M; Kaltsas G; Randeva HS
Eur J Clin Invest; 2018 Jul; 48(7):e12961. PubMed ID: 29845629
[TBL] [Abstract][Full Text] [Related]
50. Dynamic evaluation of prolactin secretion by successive TRH and metoclopramide stimulations.
Kauppila A; Heikkinen J; Viinikka L
Acta Endocrinol (Copenh); 1986 Jan; 111(1):10-6. PubMed ID: 3080846
[TBL] [Abstract][Full Text] [Related]
51. Prolactin and placental hormone levels during pregnancy in prolactinomas.
Batrinos ML; Panitsa-Faflia C; Anapliotou M; Pitoulis S
Int J Fertil; 1981; 26(2):77-85. PubMed ID: 6114069
[TBL] [Abstract][Full Text] [Related]
52. The possible prognostic value of serum prolactin increment during pregnancy in hyperprolactinaemic patients.
Andersen AN; Starup J; Tabor A; Jensen HK; Westergaard JG
Acta Endocrinol (Copenh); 1983 Jan; 102(1):1-5. PubMed ID: 6823776
[TBL] [Abstract][Full Text] [Related]
53. Basal, pulsatile, entropic, and 24-hour rhythmic features of secondary hyperprolactinemia due to functional pituitary stalk disconnection mimic tumoral (primary) hyperprolactinemia.
Veldman RG; Frölich M; Pincus SM; Veldhuis JD; Roelfsema F
J Clin Endocrinol Metab; 2001 Apr; 86(4):1562-7. PubMed ID: 11297584
[TBL] [Abstract][Full Text] [Related]
54. Prolactin gene expression in human growth hormone-secreting pituitary adenomas.
Nagaya T; Seo H; Kuwayama A; Sakurai T; Tsukamoto N; Sugita K; Matsui N
J Neurosurg; 1990 Jun; 72(6):879-82. PubMed ID: 2338572
[TBL] [Abstract][Full Text] [Related]
55. Somatostatin receptor subtype 1 selective activation in human growth hormone (GH)- and prolactin (PRL)-secreting pituitary adenomas: effects on cell viability, GH, and PRL secretion.
Zatelli MC; Piccin D; Tagliati F; Ambrosio MR; Margutti A; Padovani R; Scanarini M; Culler MD; degli Uberti EC
J Clin Endocrinol Metab; 2003 Jun; 88(6):2797-802. PubMed ID: 12788890
[TBL] [Abstract][Full Text] [Related]
56. Abnormal LH pulsatility in women with hyperprolactinaemic amenorrhoea normalizes after bromocriptine treatment: deconvolution-based assessment.
Sartorio A; Pizzocaro A; Liberati D; De Nicolao G; Veldhuis JD; Faglia G
Clin Endocrinol (Oxf); 2000 Jun; 52(6):703-12. PubMed ID: 10848874
[TBL] [Abstract][Full Text] [Related]
57. Interferon-alpha-2a is a potent inhibitor of hormone secretion by cultured human pituitary adenomas.
Hofland LJ; de Herder WW; Waaijers M; Zuijderwijk J; Uitterlinden P; van Koetsveld PM; Lamberts SW
J Clin Endocrinol Metab; 1999 Sep; 84(9):3336-43. PubMed ID: 10487708
[TBL] [Abstract][Full Text] [Related]
58. Is pregnancy the best treatment for hyperprolactinaemia?
Crosignani PG; Mattei AM; Scarduelli C; Cavioni V; Boracchi P
Hum Reprod; 1989 Nov; 4(8):910-2. PubMed ID: 2575622
[TBL] [Abstract][Full Text] [Related]
59. Abnormal twenty-four hour pattern of pulsatile luteinizing hormone secretion and the response to naloxone in women with hyperprolactinaemic amenorrhoea.
Tay CC; Glasier AF; Illingworth PJ; Baird DT
Clin Endocrinol (Oxf); 1993 Nov; 39(5):599-606. PubMed ID: 8252751
[TBL] [Abstract][Full Text] [Related]
60. Effects of naloxone on prolactin-secreting pituitary adenomas.
Shima K; Chigasaki H; Seki K
Neurol Med Chir (Tokyo); 1990 Feb; 30(2):109-12. PubMed ID: 1695330
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
